Zusammenfassung
Hintergrund
Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) sind autoimmun-entzündliche Erkrankungen des Zentralnervensystems (ZNS), die vorrangig Frauen betreffen. Ein Teil dieser Patientinnen erkrankt im gebärfähigen Alter, sodass Beratungsbedarf bezüglich Familienplanung und Schwangerschaften bestehen kann.
Ziel
Die aktuelle Publikation liefert einen Überblick zu den Themen Fertilität, Schwangerschaftskomplikationen und den Einfluss einer Schwangerschaft auf den NMOSD-Krankheitsverlauf. Darüber hinaus werden Therapieoptionen während der Schwangerschaft dargestellt.
Material und Methoden
Mithilfe der Datenbank PubMed erfolgte eine Recherche der aktuellen Literatur.
Ergebnisse und Diskussion
Tierexperimentelle Studien weisen auf Einschränkungen der Fertilität bei NMOSD hin, zur Fertilität von NMOSD-Patientinnen existieren bislang jedoch keine ausreichenden Daten. Eine Schwangerschaft bei NMOSD-Patientinnen geht mit einer erhöhten postpartalen Krankheitsaktivität sowie einem höheren Grad der Behinderung nach einer Schwangerschaft einher. Es liegen Hinweise auf ein erhöhtes Risiko für Schwangerschaftskomplikationen wie Spontanaborte und eine Präeklampsie vor. Zur Therapie eines akuten Schubs während einer Schwangerschaft können Methylprednisolon und/oder Plasmapherese/Immunadsorption eingesetzt werden. Das Absetzen bzw. die Fortführung einer immunsuppressiven Therapie mit Azathioprin oder Rituximab sollte kritisch unter Berücksichtigung der bisherigen Krankheitsaktivität abgewogen werden. Daher ist eine Mitbetreuung von NMOSD-Patienten, insbesondere in besonderen Situationen wie einer Schwangerschaft, durch spezialisierte Zentren empfehlenswert.
Abstract
Background
Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune inflammatory diseases of the central nervous system that mainly affect women. In some of these patients NMOSD occurs during fertile age. For this reason, treating physicians may be confronted with questions concerning family planning, pregnancy and birth.
Objective
This study provides an overview on the influence of NMOSD on fertility, pregnancy complications and pregnancy outcome. The effect of pregnancy on NMOSD course and therapy options during pregnancy are discussed.
Material and methods
A search of the current literature was carried out using the PubMed database.
Results and conclusion
Animal studies have shown lower fertility rates in NMOSD; however, studies investigating fertility in NMOSD patients are lacking. Pregnancy in NMOSD patients are associated with an increase in postpartum disease activity and a higher grade of disability after pregnancy. Some studies showed higher risks of pregnancy complications e. g. spontaneous abortions and preeclampsia. With a few limitations, acute relapses during pregnancy can be treated with methylprednisolone and/or plasma exchange/immunoadsorption. Stopping or continuing immunosuppressive therapy with azathioprine or rituximab during pregnancy should be critically weighed considering previous and current disease activity. Therefore, a joint supervision by a specialized center is recommended, particularly in specific situations such as pregnancy.
Literatur
Abboud H, Petrak A, Mealy M et al (2016) Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 22:185–192. https://doi.org/10.1177/1352458515581438
Abou-Nassar K, Karsh J, Giulivi A, Allan D (2010) Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss. Transfus Apher Sci 43:29–31. https://doi.org/10.1016/j.transci.2010.05.002
Alami Z, Agier MS, Ahid S et al (2017) Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie. https://doi.org/10.1016/j.therap.2017.06.006
Araki M, Matsuoka T, Miyamoto K et al (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82:1302–1306. https://doi.org/10.1212/WNL.0000000000000317
Asgari N, Flanagan EP, Fujihara K et al (2017) Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 4:e343. https://doi.org/10.1212/NXI.0000000000000343
Bennett JL, O’Connor KC, Bar-Or A et al (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e104. https://doi.org/10.1212/NXI.0000000000000104
Bennett JL, de Seze J, Lana-Peixoto M et al (2015) Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 21:678–688. https://doi.org/10.1177/1352458514567216
Bermas BL (2014) Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 26:334–340. https://doi.org/10.1097/BOR.0000000000000054
bfarm (2018) Intravenöse Immunglobuline bei der Multiplen Sklerose. http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/BereitsZugelAM/offlabel/Bewertungen/Neuro/IVIG_MS.pdf. Zugegriffen: 24. Aug. 2017
Bonnan M, Cabre P (2012) Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012:787630. https://doi.org/10.1155/2012/787630
Bonnet F, Mercié P, Morlat P et al (1999) Devic’s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 8:244–247. https://doi.org/10.1191/096120399678847696
Bontadi A, Ruffatti A, Marson P et al (2012) Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 27:200–204. https://doi.org/10.1002/jca .21229
Borisow N, Döring A, Pfueller CF et al (2012) Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 3:9. https://doi.org/10.1186/1878-5085-3-9
Borisow N, Kleiter I, Gahlen A et al (2017) Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler 23:1092–1103. https://doi.org/10.1177/1352458516671203
Bourre B, Marignier R, Zéphir H et al (2012) Neuromyelitis optica and pregnancy. Neurology 78:875–879. https://doi.org/10.1212/WNL.0b013e31824c466f
Bove R, Elsone L, Alvarez E et al (2017) Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000000339
Coelho J, Beaugerie L, Colombel JF et al (2011) Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60:198–203. https://doi.org/10.1136/gut.2010.222893
Confavreux C, Hutchinson M, Hours MM et al (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339:285–291. https://doi.org/10.1056/NEJM199807303390501
Cox JL, Koepsell SA, Shunkwiler SM (2017) Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher 32:191–195. https://doi.org/10.1002/jca .21468
Davoudi V, Keyhanian K, Bove RM, Chitnis T (2016) Immunology of neuromyelitis optica during pregnancy. Neurol Neuroimmunol Neuroinflamm 3:e288. https://doi.org/10.1212/NXI.0000000000000288
DeWitte DB, Buick MK, Cyran SE, Maisels MJ (1984) Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 105:625–628
El-Haieg DO, Zanati MF, El-Foual FM (2007) Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 99:236–241. https://doi.org/10.1016/j.ijgo.2007.05.045
Elsone L, Panicker J, Mutch K et al (2014) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 20:501–504. https://doi.org/10.1177/1352458513495938
Embryotox (2017) http//www.embyotox.de. Zugegriffen: 24. Aug. 2017
Fragoso YD, Adoni T, Bichuetti DB et al (2013) Neuromyelitis optica and pregnancy. J Neurol 260:2614–2619. https://doi.org/10.1007/s00415-013-7031-y
Friedrichs B, Tiemann M, Salwender H et al (2006) The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91:1426–1427
Hertwig L, Pache F, Romero-Suarez S et al (2016) Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler 22:160–173. https://doi.org/10.1177/1352458515586084
Hoeltzenbein M, Beck E, Rajwanshi R et al (2016) Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 46:238–245. https://doi.org/10.1016/j.semarthrit.2016.05.004
Hoffmann F, Kraft A, Heigl F et al (2015) Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding. Nervenarzt 86:179–186. https://doi.org/10.1007/s00115-014-4239-8
Jarius S, Kleiter I, Ruprecht K et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 13(281). https://doi.org/10.1186/s12974-016-0719-z
Jarius S, Paul F, Franciotta D et al (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214. https://doi.org/10.1038/ncpneuro0764
Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13:279. https://doi.org/10.1186/s12974-016-0717-1
Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280. https://doi.org/10.1186/s12974-016-0718-0
Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https://doi.org/10.1186/1742-2094-9-14
Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176:149–164. https://doi.org/10.1111/cei.12271
Jharap B, de Boer NKH, Stokkers P et al (2014) Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 63:451–457. https://doi.org/10.1136/gutjnl-2012-303615
Jurewicz A, Selmaj K (2015) Relapse of neuromyelitis optica during pregnancy—treatment options and literature review. Clin Neurol Neurosurg 130:159–161. https://doi.org/10.1016/j.clineuro.2014.12.023
Kim W, Kim S‑H, Nakashima I et al (2012) Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78:1264–1267. https://doi.org/10.1212/WNL.0b013e318250d812
Klawitter E, Bove R, Elsone L et al (2017) High risk of post-partum relapses in neuromyelitis optica spectrum disorder. Neurology 89:2238. https://doi.org/10.1212/WNL.0000000000004681
Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206–216. https://doi.org/10.1002/ana.24554
Klink DT, van Elburg RM, Schreurs MWJ, van Well GTJ (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B‑cell development. Clin Dev Immunol. https://doi.org/10.1155/2008/271363
Körtvélyessy P, Breu M, Pawlitzki M et al (2017) ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurol Neuroimmunol Neuroinflamm 4:e335. https://doi.org/10.1212/NXI.0000000000000335
Kremer L, Mealy M, Jacob A et al (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20:843–847. https://doi.org/10.1177/1352458513507822
Magraner MJ, Coret F, Casanova B (2013) The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 28:65–72. https://doi.org/10.1016/j.nrl.2012.03.014
Metz I, Beißbarth T, Ellenberger D et al (2016) Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3:e204. https://doi.org/10.1212/NXI.0000000000000204
Nakajima K, Watanabe O, Mochizuki M et al (2016) Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol 26:667–671. https://doi.org/10.3109/14397595.2016.1147405
Nakamura Y, Yoshida K, Itoh S et al (1999) Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 41:307–311
Nour MM, Nakashima I, Coutinho E et al (2016) Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 86:79–87. https://doi.org/10.1212/WNL.0000000000002208
Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671–1672
Pache F, Wildemann B, Paul F, Jarius S (2017) Neuromyelitis optica. Fortschr Neurol Psychiatr 85:e1. https://doi.org/10.1055/s-0035-1567186
Pache F, Zimmermann H, Mikolajczak J et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 13:282. https://doi.org/10.1186/s12974-016-0720-6
Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21:845–853. https://doi.org/10.1177/1352458515572406
Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392. https://doi.org/10.1002/1096-9926(200012)62:6〈385::AID-TERA5〉3.0.CO;2-Z
Pellkofer HL, Suessmair C, Schulze A et al (2009) Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 15:1006–1008. https://doi.org/10.1177/1352458509106512
Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964–968. https://doi.org/10.1001/archneur.63.7.964
Plauborg AV, Hansen AV, Garne E (2016) Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Res Part A Clin Mol Teratol 106:494–499. https://doi.org/10.1002/bdra.23509
Proia A, Paesano R, Torcia F et al (2002) Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature. Ann Hematol 81:210–214. https://doi.org/10.1007/s00277-001-0426-3
Reindl M, Rostasy K (2015) MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2:e60. https://doi.org/10.1212/NXI.0000000000000060
Reuss R, Rommer PS, Brück W et al (2009) A woman with acute myelopathy in pregnancy: case outcome. BMJ 339:b4026
Ringelstein M, Ayzenberg I, Harmel J et al (2015) Long-term therapy with Interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72:756–763. https://doi.org/10.1001/jamaneurol.2015.0533
Ringelstein M, Harmel J, Distelmaier F et al (2013) Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler 19:1544–1547. https://doi.org/10.1177/1352458513498125
Saadoun S, Waters P, Leite MI et al (2013) Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol 191:2999–3005. https://doi.org/10.4049/jimmunol.1301483
Schmidt F, Zimmermann H, Mikolajczak J et al (2017) Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 11:45–50. https://doi.org/10.1016/j.msard.2016.11.008
Schneider E, Zimmermann H, Oberwahrenbrock T et al (2013) Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS ONE 8:e66151. https://doi.org/10.1371/journal.pone.0066151
Sepúlveda M, Armangué T, Sola-Valls N et al (2016) Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 3:e225. https://doi.org/10.1212/NXI.0000000000000225
Shang W, Liu J (2011) Neuromyelitis optica during pregnancy. Int J Gynaecol Obstet 115:66–68. https://doi.org/10.1016/j.ijgo.2011.05.016
Shimizu Y, Fujihara K, Ohashi T et al (2016) Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler 22:1413–1420. https://doi.org/10.1177/1352458515583376
Sinnecker T, Dörr J, Pfueller CF et al (2012) Distinct lesion morphology at 7‑T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 79:708–714. https://doi.org/10.1212/WNL.0b013e3182648bc8
Sinnecker T, Kuchling J, Dusek P et al (2015) Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. EPMA J 6:16. https://doi.org/10.1186/s13167-015-0038-y
Sinnecker T, Schumacher S, Mueller K et al (2016) MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7 T. Neurol Neuroimmunol Neuroinflamm 3:e259. https://doi.org/10.1212/NXI.0000000000000259
Spadaro M, Gerdes LA, Krumbholz M et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3:e257. https://doi.org/10.1212/NXI.0000000000000257
Stellmann J‑P, Krumbholz M, Friede T et al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatr 88:639–647. https://doi.org/10.1136/jnnp-2017-315603
Sun X‑L, Ding J‑H, Fan Y et al (2007) Aquaporin 4 regulates the effects of ovarian hormones on monoamine neurotransmission. Biochem Biophys Res Commun 353:457–462. https://doi.org/10.1016/j.bbrc.2006.12.040
Sun X‑L, Zhang J, Fan Y et al (2009) Aquaporin-4 deficiency induces subfertility in female mice. Fertil Steril 92:1736–1743. https://doi.org/10.1016/j.fertnstert.2008.07.1785
Thomas C, Monteil-Ganiere C, Mirallié S et al (2017) A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn’s disease. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjx123
Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16. https://doi.org/10.1007/s00415-013-7169-7
Weinshenker BG, Wingerchuk DM (2017) Neuromyelitis spectrum disorders. Mayo Clin Proc 92:663–679. https://doi.org/10.1016/j.mayocp.2016.12.014
Wildemann B, Jarius S, Paul F (2013) Neuromyelitis optica. Nervenarzt 84:436–441. https://doi.org/10.1007/s00115-012-3602-x
Wingerchuk DM (2009) Neuromyelitis optica: effect of gender. J Neurol Sci 286:18–23. https://doi.org/10.1016/j.jns.2009.08.045
Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2:e62. https://doi.org/10.1212/NXI.0000000000000062
Zekeridou A, Lennon VA (2015) Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2:e110. https://doi.org/10.1212/NXI.0000000000000110
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
F. Paul gehört dem wissenschaftlichen Beirat von Novartis an, erhielt Vortragshonorare und Reisekostenerstattungen von Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune und Shire, ist Academic Editor von PLoS One, ist Associate Editor von Neurology® Neuroimmunology & Neuroinflammation; übte Beratertätigkeiten für Sanofi-Genzyme, Biogen Idec, MedImmune, Shire und Alexion aus; erhielt Forschungsunterstützung von Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, von der Deutschen Forschungsgemeinschaft, Werth Stiftung der Stadt Köln, Bundesministerium für Bildung und Forschung, Arthur Arnstein Stiftung Berlin, EU FP7 Rahmenprogramm, Guthy Jackson Charitable Foundation und National Multiple Sclerosis of the USA. K. Hellwig weist auf folgende Beziehungen hin: Beratertätigkeiten und Vortragshonorare, sowie Forschungsunterstützung von Bayer Healthcare, Biogen, Novartis Pharma, Teva Pharma, Roche, Sanofi-Genzyme und Merck. N. Borisow gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Borisow, N., Hellwig, K. & Paul, F. Neuromyelitis-optica-Spektrum-Erkrankung und Schwangerschaft. Nervenarzt 89, 666–673 (2018). https://doi.org/10.1007/s00115-018-0486-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-018-0486-4
Schlüsselwörter
- Fertilität
- Schwangerschaftskomplikationen
- Methylprednisolon
- Immunsuppressive Therapie
- Postpartale Krankheitsaktivität